tbuckley/cabot-search huggingface dataset:
Facing Addiction in the United States
Authors: Vivek H. Murthy
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0845 A Rare Cause of Anterior Knee Pain and Limitation of Knee Extension: Symptomatic Infrapatellar Plica
Authors: B. Karslıoğlu, Y. Erdem, T. Dandinoglu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The synovial plica of the knee is recognized as a structure that represents remnants of synovial membranes in embryonic development of knee. Infrapatellar plica (IP) known as the ligamentum mucosum, arises from the anterior part of intercondylar notch of femur, widens as it descends anteriorly, and runs parallel to and above the anterior cruciate ligament and attaches to the infrapatellar fat. <h3>Objectives</h3> In this report, two cases of symptomatic infrapatellar plica which caused anterior knee pain and knee extension limitation were presented. The first case was 23 years old construction worker who admitted with complains of the left anterior knee pain and limitation of knee motion. The second case was a 21 years old amateur footballer with the complaints of knee movement limitation and anterior knee pain while crouching. <h3>Methods</h3> Although we detected infrapatellar plica on MR images of the first patient (Fig. 1a and 1b), the second patient showed no evidence of infrapatellar plica on MR sequences. Arthroscopic surgery planned for the patients and plica excision applied. <h3>Results</h3> Physical therapy started just right after surgery and there were no pain or knee motion limitation at routine inspection of patients at 1,5–3-6–12 months. <h3>Conclusions</h3> These cases demonstrate a potential role for the infrapatellar plica as a cause of anterior knee pain and movement limitation.We emphasize that with the patients who suffer from anterior knee pain and knee motion limitation, one should need to keep in mind the symptomatic infrapatellar plica. <h3>Disclosure of Interest</h3> None declared
Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma with Double-Unit Cord Blood Transplantation Provides a Platform for Further Optimization
Authors: Parastoo B Dahi, Craig S. Sauter, Sean M. Devlin, Marissa N Lubin, Doris M. Ponce, Sergio Giralt, Guenther Koehne, Miguel-Angel Perales, Andrew D. Zelenetz, Craig H. Moskowitz, Juliet N. Barker
Journal: Blood (2014)
LYL1, Class II Basic Helix-Loop-Helix Transcription Factor, Induces the Differentiation of Common Marmoset Embryonic Stem Cells to Hematopoietic Stem Cells
Authors: Hirotaka Kawano, Tomotoshi Marumoto, Michiyo Okada, Tomoko Inoue, Takenobu Nii, Jiyuan Liao, Saori Yamaguchi, Yoko Nagai, Hiroyuki Inoue, Erika Sasaki, Yoshie Miura, Kenzaburo Tani
Journal: Blood (2011)
THU0332 The Predictive Risk Factors and Prognoses of Thrombotic Microangiopathy in Systemic Lupus Erythematosus
Authors: J. Li, Z. Zhang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) with thrombotic microangiopathy (TMA) has been reported in numerous patients with high mortality and poor renal prognosis. The risk factors and prognoses of these patients remain unknown. <h3>Objectives</h3> The aim of this study is to investigate the predictive risk factors of TMA in SLE patients and analyze the prognoses. <h3>Methods</h3> Clinical and laboratory parameters of 42 patients (SLE with TMA) and 84 patients (active lupus patients without TMA) were retrospectively analyzed. Clinical and laboratory data was also compared between 17 patients with renal-limited TMA and 25 patients with TTP-HUS. Logistic regression and Kaplan-Meier survival curves were statistically tested with the logrank test. HRs and their 95% CIs were calculated using the multivariate Cox proportional-hazards model. <h3>Results</h3> SLE patients with TMA suffered more neurological and cardiac involvements, as well as poor renal function. More plasma was exchanged (42.9% vs. 2.4%) and infused (64.3% vs. 40.5%) in these patients. Serological creatinine and C-reactive protein were independent risk factors for TMA. TMA patients presented poorer outcome (P=0.024), while a longer survival was expected in renal-limited TMA patients (P=0.046). In lupus patients with TMA, serum creatinine value (hazard ratio=1.005, P=0.014) and C-reactive protein levels (hazard ratio=1.009, P=0.058) predicted poor outcome. <h3>Conclusions</h3> Serum creatinine value and C-reactive protein levels were predictive for lupus with TMA. Renal-limited TMA patients presented relatively better outcome than patients with TTP-HUS. <h3>References</h3> Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013;15:R12. Hamasaki K, Mimura T, Kanda H, Kubo K, Setoguchi K, Satoh T, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol 2003;22:355–8. <h3>Acknowledgement</h3> The authors would like to thank doctor Guangtao Li and Yanjie Hao for statistic analysis guidance in Peking University First Hospital. The authors also thank to Professor Feng Yu and Doctor Yun Pang for their follow-up of these patients in Nephrology Department of Peking University First Hospital. <h3>Disclosure of Interest</h3> None declared
DHPLC Scan of Iron Genes in Consecutive Patients with Suspected Iron Overload.
Authors: Domenico Girelli, Giorgio Biasiotto, Barbara Foglieni, Claudia Bozzini, Anna Polotti, Francesca Ferrari, Ilaria Tenuti, Gian Mario Gerardi, Laura Cremonesi, Roberto Corrocher, Paolo Arosio
Journal: Blood (2004)
Critical and Complementary Role of FLT3 and Interleukin 7-Receptor Alpha Signaling in T Lymphocyte Development.
Authors: Natalija Buza-Vidas, Henrik Ahlenius, Corrado M. Cilio, Marcus Svensson, William Agace, Sten Eirik W. Jacobsen, Ewa Sitnicka
Journal: Blood (2004)
Human Monocyte-Derived Dendritic Cells Are Tolerogenic through Both IDO1 and IDO2
Authors: Sara Trabanelli, Antonio Curti, Darina Očadlíková, Cecilia Evangelisti, Valentina Salvestrini, Richard Metz, Lisa Laury-Kleintop, George Prendergast, Roberto M. Lemoli
Journal: Blood (2010)
Gingivitis and Insulin Resistance in Obese Children
Authors: Patricia Lucia Casavalle, Fima Lifshitz, Laura S. Romano, Maria Macarena Gonzalez Chaves, Noemí Bordoni, Patricia Mónica Boyer, Patricia Noemi Rodriguez, Silvia Maria Friedman
Journal: Diabetes Care (2016)

The relationship between obesity and periodontal disease (PD) in adults is well known (1). However, PD is much less frequent in pediatric populations, although gingivitis is often documented. Untreated gingivitis may progress to a more complex destructive chronic PD later in life (2). Children who are obese (OB) or overweight (OWt) may also present other comorbidities such as dyslipidemia and/or insulin resistance (IR), which may also contribute to the development of inflammatory processes observed in PD. We studied the occurrence of gingival inflammation related to excess body fat, dyslipidemia, and IR in 90 white healthy Argentinean children/adolescents. Children/adolescents were referred to the outpatient Nutrition Clinic, Hospital Jose de San Martin, School of Medicine, University of Buenos Aires, for assessment and treatment of obesity. The ethical committees of the hospital and the university approved the study. Excess …
The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia
Authors: Aaron D Maybury, Ephraim P. Hochberg, Lori J Wirth, Jeremy S. Abramson, Kevin S Emerick, James S. Michaelson, Christiana E. Toomey, Kristina Cibor, Brad Diephuis, Devon Bush
Journal: Blood (2011)
Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study
Authors: Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L Scott, Paul C. Hendrie, Elihu H. Estey
Journal: Blood (2013)
Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.
Authors: Michael R. Bishop, Seth Steinberg, Nancy M. Hardy, Steven Z. Pavletic, Ronald E. Gress, Rachel B. Salit, Paula Layton, Daniel H. Fowler
Journal: Blood (2010)
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
Authors: Cristina Rozo, Yurii Chinenov, Reena Khianey Maharaj, Sanjay Gupta, Laura Leuenberger, Kyriakos A Kirou, Vivian P Bykerk, Susan M Goodman, Jane E Salmon, Alessandra B Pernis
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Deregulated production of interleukin (IL)-17 and IL-21 contributes to the pathogenesis of autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Production of IL-17 and IL-21 can be regulated by ROCK2, one of the two Rho kinases. Increased ROCK activation was previously observed in an SLE cohort. Here, we evaluated ROCK activity in a new SLE cohort, and an RA cohort, and assessed the ability of distinct inhibitors of the ROCK pathway to suppress production of IL-17 and IL-21 by SLE T cells or human Th17 cells. <h3>Methods</h3> ROCK activity in peripheral blood mononuclear cells (PBMCs) from 29 patients with SLE, 31 patients with RA and 28 healthy controls was determined by ELISA. SLE T cells or in vitro-differentiated Th17 cells were treated with Y27632 (a pan-ROCK inhibitor), KD025 (a selective ROCK2 inhibitor) or simvastatin (which inhibits RhoA, a major ROCK activator). ROCK activity and IL-17 and IL-21 production were assessed. The transcriptional profile altered by ROCK inhibitors was evaluated by NanoString technology. <h3>Results</h3> ROCK activity levels were significantly higher in patients with SLE and RA than healthy controls. Th17 cells exhibited high ROCK activity that was inhibited by Y27632, KD025 or simvastatin; each also decreased IL-17 and IL-21 production by purified SLE T cells or Th17 cells. Immune profiling revealed both overlapping and distinct effects of the different ROCK inhibitors. <h3>Conclusions</h3> ROCK activity is elevated in PBMCs from patients with SLE and RA. Production of IL-17 and IL-21 by SLE T cells or Th17 cells can furthermore be inhibited by targeting the RhoA-ROCK pathway via both non-selective and selective approaches.
FRI0481 No Change in Self-Reported Pain from Pre-Pregnancy To Six Months Postpartum in Women with Juvenile Idiopathic Arthritis: Table 1.
Authors: B. Jakobsen, H.S. Koksvik, K. Ursin, M. Wallenius
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There are no previous studies on health related quality of life (HRQL) related to pregnancy in women with juvenile idiopathic arthritis (JIA). One study on a small population with rheumatoid arthritis (RA) using the short form 36 (SF-36) to measure HRQL, has shown that RA women reported a worsening in the aspect of bodily pain 12 and 24 weeks postpartum compared to pre-pregnancy (1). <h3>Objectives</h3> To study the impact of pregnancy on the aspect of bodily pain aspect in self- reported HRQL using SF-36 from pre-pregnancy to six months postpartum on women with JIA. <h3>Methods</h3> 25 women with JIA were followed from pre-pregnancy to six months postpartum. HRQL was measured using the SF-36 form resulting in eight multi-item subscales. In this study the aspect of bodily pain in SF-36 was explored. Registrations were recorded pre-pregnancy (within one year before conception), 1st trimester (1–12 weeks), 2nd trimester (13–27 weeks), 3rd trimester (28–40 weeks), six weeks and six months postpartum. The Wilcoxon test for related samples was performed. <h3>Results</h3> Mean age of the JIA women was 29 years (range 20–36) and mean disease duration 21 years (range 4–32). The mean number of DMARDs used before pregnancy was 0.64 (range 0–2). Correspondingly, the mean number of DMARDs were 0.68 (range 0–1) six months postpartum. The pre-pregnancy scores were tested to each of the other time points. There was a statistically significantly improvement in self-reported pain from pre-pregnancy to six weeks postpartum (p=0.019), but no difference was observed at six months postpartum. <h3>Conclusions</h3> There was a no statistically significant change in self-reported pain from pre-pregnancy to six months postpartum, but a significantly improvement was seen from pre-pregnancy to six weeks postpartum in this study population of JIA women. <h3>References</h3> Förger F, Østensen M, Schumacher A, et al. Impact of pregnancy on health related quality of life evaluated prospectively in pregnant women with rheumatic diseases by the SF-36 health survey. Annals of the rheumatic diseases 2005; 64: 1494–9. <h3>Disclosure of Interest</h3> None declared
Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.
Authors: Emilia Mahoney, Sara L Cole, Kami Maddocks, Joseph M. Flynn, Jeffrey A. Jones, Xiaoli Zhang, John C. Byrd, Amy J. Johnson
Journal: Blood (2012)
Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade®): A Study on Efficacy, Tolerance, Survival and Time to Progression
Authors: Mauricette Michallet, Mohamad Sobh, Quoc Hung Le, Fiorenza Barraco, Charles Dumontet, Youcef Chelghoum, Emmanuelle Nicolas-Virelizier, Xavier Thomas, Aline Praire, Claudiu Plesa, Giovanna Cannas, Franck Emmanuel Nicolini, Jacques Troncy
Journal: Blood (2008)
Retrospective Exploratory Study of HIV+ Patients with and without Paraproteinemia for Association with HIV Status, Comorbidities and Development of Hematological Malignancies
Authors: Erin Jou, Diwakar Mohan, Sabarish Ayyappan, Oleg Gligich, Henny Heisler Billett, Anthony T.C. Chan, Radha Raghupathy
Journal: Blood (2012)
Mud bath therapy in osteoarthritis: effects on clinics, ultrasonography and cytokines in a one year follow-up.
Authors: Ceccarelli Fulvia, Perricone Carlo, Alessandri Cristiano, Modesti Maria Grazia, Croia Cristina, Anna Maria Iagnocco, A. Fraioli, Valesini Guido
Journal: Annals of the Rheumatic Diseases (2009)
Post-translational Control of Intracellular Pathogen Sensing Pathways
Authors: Cindy Chiang, Michaela U. Gack
Journal: Trends in Immunology (2016)

Mammalian cells recognize virus-derived nucleic acids using a defined set of intracellular sensors including the DNA sensors cyclic GMP-AMP (cGAMP) synthase (cGAS) and interferon gamma (IFNγ)-inducible protein 16 (IFI16) as well as viral RNA receptors of the retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family. Following innate immune recognition, these sensors launch an immune response that is characterized by the transcriptional upregulation of many antiviral molecules, including proinflammatory cytokines, chemokines, and IFN-stimulated genes. Recent studies have demonstrated that the signal transduction initiated by these sensors is sophisticatedly regulated by post-translational modifications (PTMs) resulting in a robust yet 'tunable' cytokine response to maintain immune homeostasis. Here we summarize recent advances in our understanding of how PTMs and regulatory enzymes control the signaling activity of RLRs, cGAS, and IFI16 as well as their proximal adaptor proteins.
AB0402 Efficacy of Iguratimod Alone or in Combination with Methotrxate in Patients with Rheumatoid Arthritis
Authors: T. Kawamoto, T. Umibe, S. Iida
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It has reported that Iguratimod (IGU), one of methanesulfonanilide of anti-inflamamatory agents, can inhibit anti-arthritic activity of rheumatoid arthritis (RA). IGU was approved for rheumatoid arthritis patients with inappropriate response to conventional treatments in Japan in September 2012. <h3>Objectives</h3> We aimed to assess the efficacy of IGU alone or in combination with Methotrxate (MTX) in patients with rheumatoid Arthritis <h3>Methods</h3> Patients who had an inadequqte response to MTX were enrolled. From December 2012, forty nine patients treated with IGU were analyzes retrospectively; 17 of 49 patients were treated with only IGU, 32 of 49 patients were treated with add-on IGU in combination with MTX. Disease activity and clinical response were assessed by disease activity score 28/ESR (DAS28-ESR) and EULAR response criteria, respectively. The DAS28-ESR, CRP, SDAI, CDAI at 1, 2, 3, 6, 12, 24 months from administration of IGU were examined. <h3>Results</h3> The average amount of IGU is 40.7mg in MTX group and 41.3mg in non- MTX group. The average amount of MTX was 7mg. After follow up 24 months, escape cases was six cases. The DAS28-ESR. After 12 months of treatment, The DAS28-ESR was decreased from4.32 to 2.37 significantly in MTX group (<i>P</i>&lt;0.01), and also decreased from4.23 to 2.37 significantly in non-MTX group (<i>P</i>&lt;0.01). According to EULAR response criteria at 12 months, The DAS28-ESR remission was observed in 46.9% of patients in MTX group and 52.9% in non- MTX group. CRP decreased from1.9 to 0.7 significantly in MTX group (<i>P</i>&lt;0.01), and also decreased from 2.1 to 0.8 significantly in non-MTX group (<i>P</i>&lt;0.05).There was no significant difference between the two groups. <h3>Conclusions</h3> Based on these results, we can conclude that the treatment of IGU is effective and well tolerated, and represents a new option for RA patients, including patient with inadequqte response to MTX. <h3>References</h3> Liang-jing Lu,et al. Multicenter,dandomized,double-blind,controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis. Rheumatol 61, No. 7 July 2009:979–987 Y Aikawa, et al.An anti-rheumatic agent T-614 inhibits NF-kB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IkBα degration. Inflammation Research April 2002,Vol51 4:188–194 Xu Y, et al Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid.Medators Inflamm 2015 Dec 2.:1155 Okamura K, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol2015 Mar;25(2):235–40 <h3>Disclosure of Interest</h3> None declared
AB0033 High Mobility Group box 1 Protein Is Not Elevated in Active Phases of Giant Cell Arteritis
Authors: A. Diamantopoulos, G. Myklebust, I. Kvivik, R. Omdal
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> High mobility group box 1 (HMGB1) is a non-histone DNA-binding protein. It exists in all types of cells and has complex functions. When secreted extracellularly HMGB1 acts as an alarmin and induces and potentiates <i>NF-κB</i> activity. HMGB1 is raised in patients with active granulomatous vasculitis (1). However, a recent study did not find any association of HMGB1 protein concentration and disease activity in Giant cell arteritis (GCA) (2). Our aim was to investigate whether HMGB1 protein rises during the active phase of giant cell arteritis (GCA) and falls after initiation of treatment. <h3>Objectives</h3> Our aim was to investigate whether HMGB1 protein rises during the active phase of giant cell arteritis (GCA) and falls after initiation of treatment. <h3>Methods</h3> GCA patients were recruited at the Department of Rheumatology at the Hospital of Southern Norway in Kristiansand between January 2012 and January 2014. The diagnosis was based on positive ultrasonography of temporal arteries and /or large vessels and typical clinical manifestations. All patients fulfilled the ACR classification criteria. Blood samples were drawn at time of diagnosis and before treatment and after clinical remission. HMGB1 levels in serum were measured by ELISA (IBL International GMBH, Hamburg, Germany), using a high sensitive protocol (range 0,313–10 ng/ml). <h3>Results</h3> Fifteen GCA patients (mean age 68 years (SD 9.2), 3 males and 12 females), were included during the study period. The median time until remission was 6 months (range 1–6). Eight patients had isolated cranial arteritis while seven patients had in addition large vessel vasculitis (LVV). Mean HMGB1 concentration at diagnosis and in clinical remission were 5.5 ng/ml (SD 5.4) and 3.3 ng/ml (SD 3.0) respectively. The difference was not significant (mean difference 2.2 ng/ml (CI 95% -1.2–5.7, p=0.182), Figure 1. No differences were observed for HMGB1 concentrations at diagnosis nor at remission for cranial (p=0.2) or LVV (p=0.7). <h3>Conclusions</h3> In GCA patients, no differences in HMGB1 protein levels were observed at diagnosis compared with remission. In addition, no differences were seen between pure cranial and LVV. Thus, HMGB1 protein seems not to be a useful biomarker for disease activity in GCA. <h3>References</h3> Henes FO, Chen Y, Bley TA, Fabel M, Both M, Herrmann K, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener9s). Ann Rheum Dis. 2011;70(11):1926–9. de Souza AW, van der Geest KS, Brouwer E, Pinheiro FA, Oliveira AC, Sato EI, et al. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Res Ther. 2015;17:158. <h3>Disclosure of Interest</h3> None declared
Deregulated Activity and Localization of Glycogen Synthase Kinase 3β In Chronic Myeloid Leukemia Progenitors: Role In Leukemia Maintenance and Targeted Therapy.
Authors: Addolorata ML Coluccia, Simone De Leo, Emanuela de Luca, Giovanni Reddiconto, Ilaria Palamà, Sara Redaelli, Serena De Matteis, Carlo Gambacorti-Passerini, Luciana Dini, Michele Maffia
Journal: Blood (2010)